Fact-checked by Grok 2 weeks ago

Paracetamol

Paracetamol, also known as acetaminophen, is a synthetic non-opioid analgesic and antipyretic medication that exerts its effects primarily through central mechanisms, including activation of descending serotonergic pathways, to relieve mild to moderate pain and reduce fever.^[1]^[2] First synthesized in 1878 by American chemist Harmon Northrop Morse from p-nitrophenol, it remained largely overlooked until the 1940s and 1950s, when studies demonstrated its superior safety over related aniline derivatives like phenacetin, leading to its commercialization as a preferred alternative for everyday use.^[3]^[4] Widely recommended as a first-line treatment for pain by the World Health Organization due to its efficacy and low incidence of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs, paracetamol is available over-the-counter in many countries but carries a narrow margin of safety in overdose, where excessive dosing depletes hepatic glutathione and promotes formation of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), resulting in acute liver failure—the most common cause of drug-induced hepatotoxicity in nations like the United Kingdom and United States.^[5]^[6]^[7] While therapeutic doses pose minimal risk of hepatotoxicity even in patients with chronic liver disease, intentional or accidental overdoses exceeding 150 mg/kg in adults necessitate prompt intervention with N-acetylcysteine to mitigate severe outcomes.^[8]^[9]

Chemical Properties

Molecular Structure and Properties

Paracetamol, chemically known as N-(4-hydroxyphenyl)acetamide, possesses the molecular formula C₈H₉NO₂ and a molecular weight of 151.16 g/mol.^[10] Its structure features a benzene ring with a hydroxyl group (-OH) and an acetamido group (-NHCOCH₃) attached in the para position, contributing to its classification as a para-aminophenol derivative.^[10] Paracetamol appears as a white, odorless crystalline powder at room temperature.^[11] It has a melting point of 169–170.5 °C and a density of 1.293 g/cm³.^[11] The compound exhibits limited solubility in water, approximately 1.4 g/100 mL at 20 °C or 1 part in 70 at ambient conditions, increasing to 1 part in 20 at 100 °C; it is more soluble in ethanol (1:7) and acetone.^[11]^[12] Its boiling point exceeds 500 °C, indicating high thermal stability.^[12] In terms of acid-base properties, paracetamol displays a pKa of approximately 9.5 for the phenolic hydroxyl group, reflecting weak acidity characteristic of phenols.^[13] The molecule is achiral and does not exhibit optical activity.^[10] Crystal structure analyses reveal a monoclinic lattice, influencing its polymorphic forms relevant to pharmaceutical formulations.^[11]

Synthesis Methods

Paracetamol was first synthesized in 1877 by American chemist Harmon Northrop Morse through the reduction of p-nitrophenol using tin and hydrochloric acid, followed by acetylation.^[14] This method involved treating p-nitrophenol with tin in glacial acetic acid to yield p-aminophenol intermediate, which was then acetylated with acetic anhydride to form paracetamol.^[15] Earlier claims attribute its preparation to Charles Frédéric Gerhardt in 1852 via similar reduction of phenylacetamide, but Morse's work is widely recognized as the definitive first synthesis.^[4] In laboratory settings, paracetamol is commonly prepared via a two-step process starting from p-nitrophenol: selective reduction to p-aminophenol using reducing agents like iron or catalytic hydrogenation, followed by N-acetylation with acetic anhydride in aqueous or acidic conditions.^[16] This route achieves high yields, often exceeding 80%, and illustrates electrophilic aromatic substitution and reduction chemistries.^[16] Industrial production predominantly employs the acetylation of p-aminophenol, sourced from the nitration of phenol to p-nitrophenol (selectivity around 60-70% para isomer), followed by reduction using hydrogen over catalysts like palladium or iron filings.^[17] The acetylation step reacts p-aminophenol with acetic anhydride or acetyl chloride at 80-100°C, yielding paracetamol with purity greater than 99% after crystallization from water.^[18] This process, scaled globally in facilities across India, China, and Europe, accounts for the majority of the estimated 100,000+ tons annual output, minimizing ortho-nitrophenol byproducts through optimized nitration conditions.^[11] An alternative industrial route, the Hoechst-Celanese process introduced in the 1980s, starts from phenol via Fries rearrangement or acetylation to 4-hydroxyacetophenone (4-HAP).^[19] The 4-HAP is then oximated with hydroxylamine to form the oxime, which undergoes acid-catalyzed Beckmann rearrangement to directly yield paracetamol, bypassing the aminophenol intermediate and reducing waste from nitro reductions.^[17] This method improves atom economy, with overall yields up to 90%, and has been adopted for its efficiency in producing high-purity product without heavy metal catalysts.^[19] Emerging sustainable routes explore biomass-derived precursors, such as p-hydroxybenzoic acid from lignin, converted via Hofmann rearrangement to p-aminophenol then acetylation, aiming to replace petrochemical feedstocks.^[20] However, these remain non-dominant due to cost and scalability challenges compared to established petrochemical methods.^[20]

Pharmacology

Pharmacodynamics

Paracetamol exerts its primary therapeutic effects as an analgesic and antipyretic through central mechanisms, with its exact mode of action remaining incompletely elucidated despite extensive research.^[21] It is a weak inhibitor of cyclooxygenase (COX) enzymes, particularly in the central nervous system, where it reduces prostaglandin E2 (PGE2) synthesis that modulates pain perception and thermoregulation.^[22] Unlike non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol demonstrates minimal peripheral COX inhibition in inflamed tissues, likely due to its sensitivity to high peroxide concentrations that impair its activity in such environments, explaining its negligible anti-inflammatory effects.^[6] ^[23] The analgesic properties primarily involve selective inhibition of COX-2 or a COX-1 variant (sometimes termed COX-3) in the brain and spinal cord, leading to decreased central sensitization to nociceptive stimuli without substantially affecting gastrointestinal or platelet COX-1.^[24] ^[25] Additional central pathways include activation of descending serotonergic inhibitory systems and modulation via the metabolite N-arachidonoylphenolamine (AM404), which inhibits fatty acid amide hydrolase, enhances endocannabinoid signaling at CB1 receptors, and activates transient receptor potential vanilloid 1 (TRPV1) channels to elevate pain thresholds.^[26] ^[27] These mechanisms collectively contribute to analgesia without the peripheral prostaglandin suppression seen with NSAIDs.^[28] As an antipyretic, paracetamol acts on the hypothalamus by inhibiting COX-mediated PGE2 production, which disrupts fever-inducing signals from peripheral cytokines, thereby resetting the thermoregulatory set point.^[15] This central selectivity is supported by studies showing effective fever reduction at doses that do not significantly alter peripheral inflammation markers.^[6] Proposed alternative contributors, such as nitric oxide scavenging or indirect effects on opioid and cannabinoid systems, have been hypothesized but lack definitive causal evidence in humans.^[29] Overall, while COX inhibition provides a foundational explanation, multifaceted central interactions underscore paracetamol's profile as a non-opioid analgesic with targeted efficacy.^[30]

Pharmacokinetics

Paracetamol is rapidly and nearly completely absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations occurring within 30 to 60 minutes in adults under fasting conditions.^[22] Oral bioavailability is approximately 70-90%, influenced by first-pass hepatic metabolism, and absorption may be delayed by food intake.^[22] ^[31] The drug exhibits wide distribution throughout total body water, with a volume of distribution of about 0.9-1.0 L/kg in adults.^[22] Plasma protein binding is low at therapeutic doses (negligible to 20%), increasing to 10-25% or higher during overdose due to saturation effects.^[31] ^[22] Paracetamol undergoes extensive hepatic metabolism, accounting for over 90% of elimination at therapeutic doses. Approximately 50-60% is conjugated with glucuronic acid to form paracetamol-glucuronide, 25-35% with sulfuric acid to paracetamol-sulfate, 5-15% oxidized by cytochrome P450 enzymes (primarily CYP2E1) to the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI), and the remainder excreted unchanged.^[22] ^[31] NAPQI is normally detoxified by conjugation with glutathione, but this pathway can become saturated in overdose, leading to hepatotoxicity.^[22] Elimination follows first-order kinetics with a plasma elimination half-life of 1.5-3 hours in healthy adults, though it may extend to 2-4 hours in some populations or with hepatic impairment.^[32] Over 90% of metabolites are excreted renally within 24 hours, with less than 5% of the parent drug appearing unchanged in urine.^[22] ^[32] Total body clearance is approximately 4.5-5.5 mL/kg/min in healthy subjects.^[32]

Clinical Uses

Analgesic Applications

Paracetamol is indicated for the management of mild to moderate acute pain, including tension headaches, dental pain, musculoskeletal strains, and postoperative discomfort following minor procedures.^[22] Standard oral dosing for adults typically ranges from 500 to 1000 mg every 4 to 6 hours, not exceeding 4000 mg per day, with intravenous formulations reserved for patients unable to tolerate oral intake or requiring rapid onset in hospital settings.^[33] ^[34] In clinical guidelines for acute dental pain, paracetamol serves as a first-line option, often combined with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen for enhanced efficacy in moderate cases, achieving pain relief in the majority of patients within 30 to 60 minutes when administered at 1000 mg.^[35] For postoperative pain, such as after ambulatory surgery, single-dose paracetamol at 1000 mg provides statistically significant but modest reductions in pain intensity compared to placebo, with number needed to treat for one additional patient achieving at least 50% pain relief estimated at 5 to 8.^[36] Evidence from systematic reviews supports its application in osteoarthritis of the knee or hip, where regular dosing yields a mean difference in pain reduction of -0.3 points on a 0-10 visual analog scale versus placebo, though this benefit is modest and may not exceed the minimal clinically important difference for all patients.^[37] In contrast, applications for chronic low back pain show minimal or no clinically relevant efficacy, with meta-analyses reporting no significant difference from placebo in pain scores or function after up to 12 weeks of use at 4000 mg daily.^[38] Combinations with caffeine or weak opioids extend its utility for breakthrough pain in these contexts, demonstrating superior relief over monotherapy in randomized trials for acute migraine or tension-type headaches.^[39]

Antipyretic Effects

Paracetamol exerts its antipyretic effects primarily through central inhibition of prostaglandin E2 (PGE2) synthesis in the hypothalamus, which lowers the thermoregulatory set point elevated during fever. This action is mediated by weak inhibition of cyclooxygenase enzymes, particularly a variant of COX-1 or the proposed COX-3 isoform in the brain, rather than peripheral COX-2 as seen with non-steroidal anti-inflammatory drugs (NSAIDs).^[2]^[10]^[22] Clinical trials demonstrate that oral or intravenous paracetamol reliably reduces fever in adults and children with infectious causes, typically lowering body temperature by 1-1.5°C within 1-2 hours after a standard dose of 10-15 mg/kg in children or 1 g in adults, with effects lasting 4-6 hours. A randomized trial of 1 g intravenous paracetamol in adults with infection-related fever showed rapid onset and sustained reduction compared to baseline, though efficacy depends on hepatic metabolism. In critically ill patients with suspected infection, paracetamol produced a modest mean temperature decrease of 0.3°C over 48 hours without improving outcomes like mortality or ICU stay.^[40]^[41]^[42] Comparisons with alternatives indicate paracetamol is effective but sometimes less potent than ibuprofen for fever reduction, particularly in children under 2 years, where ibuprofen achieves greater temperature drops at 4-24 hours post-dose. High-dose paracetamol (20-30 mg/kg) outperforms standard dosing in speed and duration against agents like mefenamic acid in febrile children, though combinations with ibuprofen enhance overall efficacy without increased adverse events.^[43]^[44]^[45] Evidence supporting routine antipyretic use for fever alone is limited and inconsistent, especially in children, with systematic reviews finding weak support for paracetamol over placebo in reducing temperature without clear benefits to discomfort, illness duration, or recovery. Meta-analyses in febrile adults show no reduction in mortality risk from fever therapy (risk ratio 1.04), suggesting interventions like paracetamol primarily alleviate symptoms rather than alter disease course, as fever may confer adaptive benefits in host defense. Guidelines thus prioritize its use for comfort in symptomatic patients over normative temperature control, emphasizing that it does not address underlying infection.^[46]^[47]^[48]

Other Therapeutic Indications

Intravenous or oral paracetamol has emerged as an alternative therapy for closing hemodynamically significant patent ductus arteriosus (PDA) in preterm neonates, particularly when nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or indomethacin are contraindicated due to risks like renal impairment or gastrointestinal bleeding.^[49] A 2022 Cochrane systematic review of 20 randomized controlled trials involving over 1,400 preterm infants found that paracetamol achieves PDA closure rates of approximately 75% after one or two courses, comparable to ibuprofen (relative risk 0.90, 95% CI 0.82-0.98), with lower rates of oliguria and no significant increase in other adverse events like intraventricular hemorrhage.^[50] Typical regimens involve 15 mg/kg every 6 hours for 3-7 days, with efficacy potentially dose-dependent and higher in infants beyond 28 weeks gestation.^[51] However, evidence quality is moderate due to small sample sizes and heterogeneity, and long-term neurodevelopmental outcomes remain understudied, with one 2023 analysis showing no increased mortality risk but calling for further randomized data.^[52] In osteoarthritis (OA) of the hip or knee, paracetamol is frequently prescribed as first-line treatment for pain management, with doses up to 4 g daily.^[22] Yet, a 2019 Cochrane review of 10 high-quality trials with 3,541 participants demonstrated only minimal pain reduction (mean difference -0.49 cm on a 10 cm visual analog scale, 95% CI -0.99 to 0.01) and negligible functional improvements compared to placebo, falling below clinical significance thresholds (e.g., 9 mm pain reduction or 10% relative change).^[53] This aligns with broader overviews indicating paracetamol's effect size (0.18-0.21) is small and often outweighed by risks in chronic use, leading some guidelines to de-emphasize it in favor of non-pharmacological or alternative analgesics.^[54]^[55] For cancer pain, systematic reviews, including a 2017 Cochrane analysis of three small trials (n=135), found no reliable evidence supporting paracetamol's efficacy either as monotherapy or adjunct to opioids, with no significant differences in pain scores or opioid requirements.^[56] Similarly, it shows no benefit for acute low back pain or dental pain beyond placebo in high-quality syntheses.^[54] Emerging off-label explorations, such as neuroprotective effects or adjunctive roles in chemotherapy-induced symptoms, lack robust clinical trial support and remain speculative.^[57] Overall, indications beyond general analgesia and antipyresis are limited, with PDA closure representing the most evidence-based non-pain application.

Efficacy and Limitations

Evidence for Effectiveness

Paracetamol demonstrates efficacy as an analgesic for mild to moderate acute pain, with systematic reviews of randomized controlled trials (RCTs) indicating that a single oral dose of 1 g provides clinically meaningful relief for approximately 50% of patients, lasting about 4 hours, outperforming placebo but with a number needed to treat (NNT) of around 4 for at least 50% pain reduction. In postoperative settings, intravenous paracetamol similarly yields effective analgesia for 4 hours post-administration, supported by high-quality evidence from meta-analyses of RCTs in adults and children.^[58] For specific acute pains such as dental pain or postpartum discomfort, doses of 500–1000 mg reduce pain intensity significantly versus placebo, as evidenced by overviews of multiple RCTs aggregating data from hundreds of patients per condition.^[54] Regular consumption of paracetamol does not lead to the development of tolerance to its analgesic effects, unlike some other medications such as opioids.^[59] As an antipyretic, paracetamol lowers elevated body temperature in febrile patients, with meta-analyses of RCTs in children showing statistically significant reductions in fever compared to placebo, though resolution rates may be modestly lower than with ibuprofen (pooled odds ratio 0.91 favoring ibuprofen).^[60] In critically ill adults with suspected infection, a 1 g dose every 6 hours reduced temperature by about 0.4°C more than placebo over 48 hours, confirming a modest but reliable antipyretic effect without impacting mortality or ICU stay duration.^[41] Pediatric studies, including RCTs for post-vaccination fever, further support its role in alleviating fever and associated fussiness, with benefits observable within 1–4 hours.^[61] Evidence from combination therapies reinforces paracetamol's utility; for instance, adding codeine (60 mg) to paracetamol enhances pain relief beyond paracetamol alone in acute settings, as shown in Cochrane-reviewed trials with low adverse event rates.^[62] Intravenous formulations provide rapid onset (within 5–10 minutes) for acute pain management in surgical or emergency contexts, with RCTs demonstrating reduced opioid requirements when used adjunctively.^[63] Overall, these findings from gold-standard sources like Cochrane systematic reviews establish paracetamol as a first-line option for symptomatic relief in non-severe cases, with efficacy grounded in dose-dependent inhibition of central prostaglandin synthesis contributing to its mechanism.^[62]

Conditions with Weak or No Benefit

Paracetamol demonstrates no clinically meaningful benefit in treating low back pain. High-quality evidence from randomized placebo-controlled trials indicates it fails to reduce pain intensity (mean difference -0.5 points on a 0-10 scale, 95% CI -2.9 to 1.9), disability (mean difference 0.4 points, 95% CI -1.7 to 2.5), or improve quality of life compared to placebo.^[64] An overview of systematic reviews corroborates this, reporting high-quality evidence of ineffectiveness for acute low back pain specifically (mean difference 0.2 points on a 0-10 scale, 95% CI -0.1 to 0.4).^[54] These findings, derived from meta-analyses of over 3,500 participants across multiple trials, have prompted recommendations to reconsider its routine inclusion in clinical guidelines for this condition.^[64] In osteoarthritis, particularly of the hip or knee, paracetamol offers only minimal short-term pain relief that does not meet clinical significance thresholds. A meta-analysis of randomized trials showed a small reduction in pain scores (-3.7 mm on a 100 mm visual analogue scale, 95% CI -5.5 to -1.9) and disability (-2.9 points, 95% CI -4.9 to -0.9), but these effects are deemed negligible and insufficient to justify first-line use given potential harms.^[64] Long-term benefits remain unestablished, with no improvements in function or progression of joint disease observed.^[64] Evidence also points to weak or absent efficacy in other pain states, including sore throat from common colds and certain procedural pains such as those following dental surgery in children or hysterosalpingography, though these rely on lower-quality data from fewer trials.^[54] Paracetamol's mechanism, which lacks substantive anti-inflammatory effects, further limits its utility in conditions driven by inflammation, such as acute gouty arthritis, where non-steroidal anti-inflammatory drugs outperform it in comparative studies.^[64]

Safety Profile

Common Adverse Effects

Paracetamol is generally well-tolerated at recommended therapeutic doses, with most users experiencing no adverse effects or only mild, transient symptoms comparable to placebo in clinical trials.^[54]^[22] The most frequently reported common adverse effects include nausea, vomiting, and constipation, occurring in a small percentage of patients during short-term use.^[65] Other mild effects such as diarrhea, increased sweating, loss of appetite, and stomach cramps have been noted in post-marketing surveillance and clinical observations.^[66] Skin rashes, pruritus, and other hypersensitivity reactions represent additional common cutaneous effects, though these are infrequent and typically resolve upon discontinuation.^[22]^[10] In pediatric populations, occasional reports include drowsiness, fatigue, or transient low blood pressure, but these remain uncommon at standard doses.^[67] Overall incidence of these effects is low, with systematic reviews indicating no significant difference from placebo for any or serious adverse events in acute settings, though individual susceptibility varies.^[54]^[68]

Serious Risks Including Hepatotoxicity

Hepatotoxicity represents the primary serious risk associated with paracetamol, primarily occurring in overdose scenarios where the drug's reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), depletes hepatic glutathione stores and binds to cellular proteins, leading to centrilobular necrosis.^[69] This process is mediated by cytochrome P450 enzymes, particularly CYP2E1, which generate NAPQI in excess of detoxification capacity during high doses.^[70] Acute ingestion exceeding 150 mg/kg or 12 g in adults poses a high risk of severe liver damage, with hepatotoxicity developing in approximately 6% of cases where serum concentrations surpass 200 μg/mL at 4 hours post-ingestion.^[9]^[71] Risk factors amplifying susceptibility include chronic alcohol consumption, which induces CYP2E1 and impairs glutathione regeneration; malnutrition; underlying liver disease; and repeated supratherapeutic dosing (e.g., 4-6 g/day over days).^[72]^[73] Paracetamol accounts for about 56% of severe acute liver injury and acute liver failure cases in regions with available data, often necessitating transplantation or resulting in mortality without prompt intervention like N-acetylcysteine administration.^[74] Unintentional overdoses, particularly in those with alcohol abuse or preexisting hepatic conditions, contribute disproportionately to hepatotoxicity incidence.^[73] Beyond hepatotoxicity, other serious adverse effects are infrequent at therapeutic doses but include rare hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis.^[65] Acute kidney injury can accompany severe hepatotoxicity in overdose, affecting up to 25% of acute liver failure cases, while chronic high-dose use has been linked to potential renal impairment in some observational studies, though causality remains debated due to confounding factors like underlying conditions.^[8] Hematologic toxicities, including thrombocytopenia and agranulocytosis, occur very rarely and lack strong causal evidence at standard doses.^[65] Overall, while therapeutic use carries low risk of serious events, vigilance against cumulative dosing and individual vulnerabilities is essential to mitigate these hazards.^[75]

Considerations for Special Populations

In pediatric populations, paracetamol dosing is weight-based to minimize overdose risk, typically 10-15 mg/kg every 4-6 hours, not exceeding 60 mg/kg daily or 4 doses in 24 hours.^[22] ^[76] Overdosing occurs frequently due to non-weight-adjusted administration, with children over 3 years at higher risk of supratherapeutic doses leading to potential hepatotoxicity.^[77] While guidelines endorse its use for fever and pain, some analyses question its long-term safety in infants based on animal and human data suggesting neurodevelopmental effects, though clinical consensus supports judicious use.^[78] For elderly patients, the standard adult dose of 500-1000 mg every 4-6 hours (maximum 4 g daily) applies without routine reduction, but increased susceptibility to adverse effects arises from comorbidities, reduced hepatic function, and polypharmacy.^[79] Frail or malnourished older adults may require dose limits of 3 g daily to mitigate hepatotoxicity risk, particularly with concurrent alcohol use or low body weight.^[75] During pregnancy, paracetamol remains the preferred analgesic, but exposure—reported in over 60% of pregnancies—has been associated in multiple studies with increased risks of autism spectrum disorder, ADHD, and reduced birth weight, potentially via oxidative stress or endocrine disruption, though sibling-control analyses show weaker links and causation remains unproven.^[80] ^[81] ^[82] The FDA and professional bodies like SMFM advise its use only when necessary for pain or fever, with ongoing review of chronic exposure risks, especially near term.^[83] In lactation, it is compatible with breastfeeding, as levels in milk are low (0.04-0.23% of maternal dose) and no adverse infant effects are documented; scheduled postpartum dosing may even support breastfeeding initiation.^[84] Patients with hepatic impairment face heightened hepatotoxicity risk due to impaired glucuronidation and sulfation pathways; paracetamol is contraindicated in severe disease and limited to 2 g daily or less in mild cases, with avoidance in active liver injury.^[22] In renal impairment, no dose adjustment is generally needed for short-term use, as paracetamol is primarily hepatically metabolized, but monitoring for accumulation of metabolites is advised in end-stage disease, and AKI from overdose rarely occurs without hepatic involvement.^[85] ^[86] Chronic alcoholics should cap intake at 2-3 g daily to prevent glutathione depletion exacerbating toxicity.^[87]

Overdose and Toxicity

Mechanisms and Clinical Presentation

In therapeutic doses, paracetamol undergoes primarily phase II metabolism via glucuronidation and sulfation, with approximately 5-10% oxidized by cytochrome P450 enzymes (predominantly CYP2E1) to the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI).^[72] NAPQI is normally detoxified by conjugation with glutathione, preventing cellular damage.^[88] In overdose, saturation of conjugation pathways shifts metabolism toward CYP2E1, generating excess NAPQI that depletes hepatic glutathione stores within hours.^[89] Unbound NAPQI then covalently binds to sulfhydryl groups on cellular proteins, particularly in centrilobular hepatocytes, initiating oxidative stress, mitochondrial dysfunction, lipid peroxidation, and activation of inflammatory pathways such as JNK-mediated signaling.^[72] This cascade culminates in hepatocellular necrosis, primarily affecting zone 3 of the liver acinus due to higher CYP2E1 expression and lower oxygen tension there.^[74] Factors exacerbating toxicity include induction of CYP2E1 (e.g., by chronic alcohol use or starvation) or reduced glutathione synthesis (e.g., malnutrition).^[72] The clinical presentation of paracetamol overdose evolves in four phases, though not all patients progress uniformly, and symptoms may be absent in massive ingestions until late stages.^[90] Phase 1 (0-24 hours post-ingestion) is often characterized by nonspecific gastrointestinal symptoms such as nausea, vomiting, anorexia, and pallor, or may be entirely asymptomatic; vital signs are typically normal, with no initial evidence of hepatotoxicity.^[72] Phase 2 (24-72 hours) marks the onset of hepatic injury, featuring right upper quadrant abdominal pain, tender hepatomegaly, and markedly elevated transaminases (AST and ALT often exceeding 1,000 IU/L), alongside rising bilirubin and prothrombin time; metabolic acidosis or hypoglycemia may emerge in severe cases. Phase 3 (72-96 hours) represents the peak of toxicity, with fulminant hepatic failure manifest as jaundice, coagulopathy (INR >3.5), hepatic encephalopathy (confusion to coma), acute kidney injury, pancreatitis, and lactic acidosis; multiorgan failure occurs in approximately 1-2% of untreated severe overdoses, with mortality risk highest here.^[90] Phase 4 (>96 hours to weeks) involves either resolution with declining liver enzymes and recovery of synthetic function in survivors or progression to death from cerebral edema, sepsis, or hemorrhage; renal recovery is usual unless ATN develops.^[72] Early serum paracetamol levels, acetaminophen-protein adducts, or Rumack-Matthew nomograms guide risk stratification, as clinical signs lag behind biochemical derangements.^[90]

Management and Outcomes

Management of paracetamol overdose begins with rapid assessment of the ingestion history, including timing, amount, and co-ingestants, followed by gastrointestinal decontamination if presentation occurs within 1 to 4 hours of ingestion. Activated charcoal, administered at a dose of 1 g/kg, can reduce absorption by up to 50% in this window, though its use is not recommended beyond 4 hours due to limited efficacy and risk of aspiration.^[72]^[91] Serum paracetamol levels are then measured at a minimum of 4 hours post-ingestion and plotted on the Rumack-Matthew nomogram to stratify hepatotoxicity risk, with levels above the treatment line indicating need for antidote.^[72] The cornerstone of treatment is N-acetylcysteine (NAC), which replenishes glutathione to detoxify the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). Intravenous NAC is preferred in many guidelines for its faster onset and lower vomiting risk compared to oral administration, typically given as a loading dose of 150 mg/kg over 1 hour, followed by 50 mg/kg over 4 hours and 100 mg/kg over 16 hours, for a total of 300 mg/kg over 21 hours.^[91]^[92] NAC is most effective when initiated within 8 hours of ingestion, preventing hepatotoxicity in over 95% of cases at that stage, but remains beneficial up to 24 hours or longer in cases of established liver injury.^[93] Supportive measures include intravenous fluids for hydration, serial monitoring of liver function tests, international normalized ratio (INR), renal function, and acid-base status, with hemodialysis considered for severe metabolic acidosis or renal failure.^[72] In severe hepatotoxicity, fulfilling King's College criteria—such as arterial pH <7.3 after fluid resuscitation, INR >6.5, or combined creatinine >300 µmol/L, encephalopathy grade 3-4, and INR >3.5—indicates poor prognosis without liver transplantation, which has a survival rate exceeding 80% in eligible candidates.^[94] Outcomes are favorable with prompt NAC therapy, yielding hepatotoxicity rates below 5% and mortality under 1% in treated acute single overdoses presenting early.^[95] Delayed presentation beyond 12 hours correlates with higher risks of acute liver failure (up to 30-40% in untreated massive ingestions >30 g) and death, though NAC extends the therapeutic window, reducing mortality from historical untreated rates of 20-30% to current figures of approximately 0.5-1% in the US, where paracetamol accounts for about 500 annual overdose deaths amid 56,000 emergency visits.^[72]^[93] Chronic supratherapeutic ingestions pose challenges due to absent nomogram applicability, often requiring empirical NAC based on aminotransferase elevations >1000 IU/L, with outcomes varying by total dose and comorbidities like chronic alcohol use, which exacerbate NAPQI formation.^[92]^[96]

Epidemiological Impact

Paracetamol overdose represents a significant public health burden, accounting for approximately 6% of reported poisonings globally where data are available, and is implicated in 56% of cases of severe acute liver injury and acute liver failure.^[74] In the United States, it leads to around 56,000 emergency department visits, 2,600 hospitalizations, and 500 deaths each year, with single-substance exposures numbering 66,710 in 2022 according to poison control data.^[72]^[9] Of these, 8-31% are unintentional, often stemming from therapeutic misadventures like exceeding recommended doses over time, highlighting gaps in dosing awareness rather than solely suicidal intent.^[97] In the United Kingdom, paracetamol is the leading agent in self-poisoning, with 82,000-90,000 hospital presentations annually and 150-250 deaths, alongside 15-20 liver transplants required each year in England and Wales.^[98] Regulatory measures, such as pack size limits introduced in 1998, have reduced overdose deaths by 43%, demonstrating that restricting availability can mitigate impulsive acts without fully eliminating the risk from stockpiled supplies or intentional sourcing.^[99] Recent Scottish data from 2020-2023 show sustained high emergency attendances for paracetamol-only overdoses, with hospital admissions stable at around 2,000-3,000 yearly from 2010-2021, underscoring persistent vulnerability in young adults and females.^[100] Mortality from treated cases remains low at under 2%, but untreated or delayed presentations elevate risks, with paracetamol causing 7% of poisoning-related fatalities in surveyed regions.^[9]^[74] Long-term outcomes reveal elevated all-cause mortality post-overdose, linked to hepatic sequelae and comorbidities, emphasizing the need for follow-up care beyond acute management.^[101] In Australia, intentional paracetamol overdoses prompted over 22,000 hospital cases from 2004-2017, with stable incidence but variable outcomes tied to antidote access.^[102] These patterns reflect paracetamol's widespread over-the-counter availability as a key causal factor, outweighing alternatives like ibuprofen in overdose frequency due to lower acute toxicity barriers.^[103]

Drug Interactions

Pharmacokinetic Interactions

Paracetamol undergoes pharmacokinetic interactions mainly affecting its absorption rate via gastric emptying modulation and its hepatic metabolism through enzyme induction or inhibition. These interactions generally do not produce serious adverse effects at therapeutic doses but may alter plasma concentration profiles.^[104] Absorption of orally administered paracetamol is rapid and dependent on gastric emptying. Agents that delay gastric emptying, including food, anticholinergics such as propantheline and atropine, and opioids like pethidine, prolong the time to peak plasma concentration (T_max) and may reduce peak levels (C_max), though bioavailability remains largely unchanged.^[32]^[105]^[106] Prokinetic drugs like metoclopramide accelerate gastric emptying, hastening absorption, shortening T_max, and increasing C_max without substantially altering the area under the curve (AUC).^[107] Lansoprazole similarly hastens absorption of paracetamol solutions, while calcium carbonate can decrease overall absorption.^[108]^[31] Hepatic metabolism, primarily via glucuronidation, sulfation, and minor CYP2E1-mediated oxidation to N-acetyl-p-benzoquinone imine (NAPQI), is influenced by certain drugs. Enzyme inducers including carbamazepine, phenytoin, phenobarbital, and chronic ethanol increase CYP2E1 activity, accelerating paracetamol clearance and NAPQI formation, which may reduce therapeutic efficacy but heightens hepatotoxicity risk in overdose.^[109]^[110]^[74] Probenecid inhibits glucuronidation and renal tubular secretion of conjugates, reducing paracetamol clearance by approximately 45% (from 6.23 to 3.42 ml/min/kg) and increasing plasma exposure, potentially necessitating dose reduction.^[111]^[112] Distribution and excretion interactions are minimal; paracetamol exhibits low protein binding and rapid tissue distribution, with metabolites excreted renally. In renal impairment, parent drug half-life is unaffected, but conjugate accumulation occurs. No confirmed pharmacokinetic interactions significantly alter distribution volume or non-renal excretion.^[113] Overall, clinically significant pharmacokinetic interactions with paracetamol are limited at standard doses, with monitoring recommended for concomitant use of enzyme inducers or probenecid.^[104]^[22]

Clinical Significance

Paracetamol exhibits a relatively low potential for clinically significant drug interactions compared to other analgesics, owing to its minimal impact on cytochrome P450 enzymes involved in the metabolism of most drugs. However, interactions that alter its hepatic metabolism—primarily via induction of CYP2E1, which increases production of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI)—can elevate the risk of hepatotoxicity, particularly in vulnerable patients. Chronic alcohol consumption, for instance, induces CYP2E1 activity, potentially amplifying paracetamol-induced liver injury even at therapeutic doses, though evidence for this effect in non-overdose scenarios remains inconsistent and primarily associative rather than causal from controlled studies.^[114]^[115] Similarly, anticonvulsants such as phenytoin and carbamazepine, which induce CYP2E1, have been linked to heightened hepatotoxicity risk, with case reports documenting elevated liver enzymes and clinical incidents in polypharmacy settings.^[116]^[117] A notable interaction occurs with warfarin, where paracetamol doses exceeding 2 g daily can dose-dependently prolong the international normalized ratio (INR), increasing bleeding risk through reductions in vitamin K-dependent clotting factors II, VII, IX, and X.^[118]^[119] This effect, observed as early as day 3 of co-administration, necessitates INR monitoring in anticoagulated patients, especially postoperatively where supratherapeutic INR may precipitate hemorrhage.^[120]^[121] Paracetamol may also reduce steady-state exposure to lamotrigine by approximately 20% via enhanced glucuronidation, potentially compromising seizure control in epileptic patients, warranting dose adjustments.^[122] Overall, while these interactions underscore the need for caution in patients with hepatic impairment, malnutrition, or polypharmacy, paracetamol's profile supports its use as a safer alternative to nonsteroidal anti-inflammatory drugs in many scenarios, provided dosing remains below 4 g daily and concomitant risks are assessed.^[104]^[123]

History

Discovery and Initial Research

Paracetamol, also known as acetaminophen, was first synthesized in 1877 by American chemist Harmon Northrop Morse at Johns Hopkins University through the reduction of p-nitrophenol with tin in the presence of glacial acetic acid.^[14]^[3] This chemical preparation yielded the compound as a white crystalline substance, though its potential therapeutic value was not immediately recognized or pursued in medical contexts.^[124] Initial pharmacological investigations occurred in the late 19th century amid research into aniline derivatives for fever reduction and pain relief. In 1893, German physiologist Joseph von Mering conducted early clinical evaluations of paracetamol, administering it to patients and reporting its antipyretic and analgesic properties in a publication that compared it to phenacetin, a related compound derived from similar synthesis pathways.^[4]^[14] Von Mering noted paracetamol's efficacy but concluded phenacetin was preferable, citing concerns over paracetamol's potential toxicity based on limited observations, which later proved unfounded.^[14] These trials represented the first documented human use of isolated paracetamol, though they were constrained by impure preparations and a lack of standardized dosing.^[125] Subsequent early research remained limited, overshadowed by the rapid adoption of acetanilide (introduced as Antifebrin following accidental discovery of its effects by Arnold Cahn and Paul Hepp in 1886) and especially aspirin after its synthesis and commercialization by Bayer in 1899.^[126]^[3] Paracetamol was occasionally identified as a urinary metabolite of phenacetin in studies around 1893, hinting at its role in the metabolism of these analgesics, but no large-scale trials or mechanistic investigations followed in the ensuing decades.^[127] This neglect persisted due to phenacetin's perceived advantages and the absence of patent protection for paracetamol, delaying deeper empirical scrutiny until post-World War II re-evaluations.^[128]

Commercialization and Patent Issues

Paracetamol's commercial introduction followed decades of limited interest after its initial synthesis in 1878, gaining traction in the mid-20th century as a safer alternative to aniline-based analgesics like phenacetin and acetanilide, which were associated with methemoglobinemia and renal toxicity. In the United States, it first appeared on the market in 1950, initially in combination products, before McNeil Laboratories launched the single-ingredient Tylenol elixir for children in 1955, marking a pivotal step in its widespread adoption as an over-the-counter analgesic and antipyretic.^[3]^[4] This development was supported by clinical studies in the 1940s demonstrating its efficacy and lower toxicity profile compared to predecessors.^[129] The absence of a compound patent for paracetamol stemmed from its public disclosure over 70 years prior to commercialization; synthesized by Harmon Northrop Morse in 1878 and tested clinically as early as 1893 by Joseph von Mering, it constituted prior art that barred exclusive intellectual property claims on the molecule itself.^[3]^[4] This public domain status enabled multiple manufacturers to produce and market generic versions shortly after introduction, fostering rapid global dissemination—such as Panadol in the United Kingdom and Australia in 1956—without legal barriers to entry.^[4] Subsequent patents focused on formulations, delivery methods, and combinations rather than the core compound, including extended-release particles patented in 2000, but these did not impede the generic dominance of standard oral paracetamol.^[10] Patent disputes have primarily arisen in niche areas, such as intravenous formulations and specific tablet designs, rather than the original oral drug; for instance, legal challenges in the 2010s contested listings for acetaminophen injection processes in regulatory compendia like the FDA's Orange Book, highlighting efforts to extend exclusivity through secondary patents amid generic competition.^[130] However, the foundational lack of molecule-specific protection ensured paracetamol's affordability and availability, contributing to its status as one of the most consumed pharmaceuticals worldwide by the 1970s.^[126]

Regulatory Evolution

Paracetamol was initially approved for therapeutic use in the United States in 1951 under prescription-only status, with widespread adoption following McNeil Laboratories' introduction of Tylenol in 1955.^[10] By 1960, the U.S. Food and Drug Administration (FDA) reclassified single-ingredient acetaminophen formulations as over-the-counter (OTC) medications, reflecting confidence in its safety profile at recommended doses.^[9] ^[131] In the United Kingdom, paracetamol gained formal recognition in the British Pharmacopoeia in 1963, becoming available OTC shortly thereafter, amid growing evidence of its efficacy as an analgesic with fewer gastrointestinal side effects than alternatives like aspirin.^[127] Concerns over hepatotoxicity from overdoses emerged in the 1960s and 1970s, prompting initial regulatory responses focused on labeling. In the U.S., the FDA mandated warning statements on OTC acetaminophen labels in 1977, advising against exceeding the recommended dose to prevent potential liver damage, following reports of acute liver failure cases.^[132] This was expanded in subsequent decades; for instance, in 1998, the FDA proposed capping OTC tablet strengths at 500 mg but ultimately permitted higher doses after industry pushback and limited evidence of broad risk.^[132] In the UK, early warnings emphasized overdose risks, but regulatory action intensified due to paracetamol's role in self-poisoning, which accounted for a significant portion of hospital admissions by the 1990s. A pivotal change occurred in the UK in September 1998, when legislation restricted pack sizes to a maximum of 32 tablets (16 g) in pharmacies and 16 tablets (8 g) in non-pharmacy outlets, aimed at curbing impulsive overdoses and suicides.^[133] ^[134] Studies evaluating this measure reported a 43% reduction in paracetamol-related deaths and a 17% drop in hospital admissions for overdoses in the decade following implementation, attributing the effect to reduced access to large quantities.^[135] ^[99] In the U.S., similar pack size limits were debated in 2009 amid rising overdose concerns, but the FDA opted against nationwide restrictions, citing insufficient evidence that they would proportionally reduce suicides given differences in poisoning patterns compared to the UK.^[132] Further U.S. refinements addressed combination products and chronic use risks. In 2011, the FDA limited acetaminophen content in prescription opioid combinations to 325 mg per dosage unit and required black-box warnings for hepatotoxicity, reducing inadvertent overdoses from multi-ingredient drugs.^[136] Internationally, variations persist; for example, some European countries like Ireland mirrored the UK's 1998 restrictions, while Australia maintains OTC status with dose limits but no universal pack caps, reflecting ongoing debates over balancing accessibility and harm reduction.^[137] Recent developments, such as the FDA's 2024 proposal for OTC labels to warn of severe skin reactions, underscore continued evolution toward enhanced risk communication.^[138]

Society and Culture

Nomenclature and Branding

Paracetamol's systematic IUPAC name is N-(4-hydroxyphenyl)acetamide, reflecting its chemical structure as a substituted acetamide with a phenolic hydroxyl group at the para position.^[10]^[139] This nomenclature derives from its origins as a derivative of p-aminophenol acetylated at the nitrogen atom.^[140] The generic name "paracetamol" is a portmanteau of "para-acetylaminophenol," emphasizing the para-substituted acetamide on the phenol ring, and was adopted internationally following its synthesis and pharmacological evaluation in the early 20th century.^[141] In contrast, "acetaminophen" is used primarily in the United States and Japan, stemming from "N-acetyl-p-aminophenol" or "para-acetamidophenol," a naming convention rooted in American pharmaceutical standardization during the drug's commercialization in the 1950s.^[141]^[31] These dual names refer to the identical compound (C₈H₉NO₂) but highlight regional differences in pharmacopeial preferences established by bodies like the United States Adopted Names (USAN) Council for acetaminophen and the British Approved Name (BAN) for paracetamol.^[10] Commercially, paracetamol is marketed under various trademarks reflecting its global availability as both branded and generic formulations. In the United States, it is predominantly branded as Tylenol by McNeil Consumer Healthcare (a Johnson & Johnson subsidiary), introduced in 1955 as a safer alternative to aspirin for children.^[31] Internationally, Panadol, developed by Frederick Stearns & Co. (later Sterling-Winthrop and now under GlaxoSmithKline), became a leading brand in the United Kingdom, Europe, Australia, and other markets starting from the late 1950s.^[142] Other notable brands include Calpol for pediatric suspensions in the UK and equivalents like Tempra in parts of Asia, though generic versions dominate due to paracetamol's off-patent status since the 1940s.^[143] These brands often emphasize formulations tailored to dosage strengths, such as 500 mg tablets, and combination products with opioids or antihistamines for enhanced analgesia.^[144]

Formulations and Global Availability

Paracetamol is formulated in multiple dosage forms to accommodate various patient needs and administration routes. Common oral preparations include immediate-release tablets and caplets typically containing 325 mg to 1000 mg per unit, extended-release caplets at 650 mg, capsules, chewable tablets, oral disintegrating tablets, effervescent tablets, powders, and liquid suspensions or solutions, often at concentrations like 120 mg/5 mL or 160 mg/5 mL for pediatric use.^[143]^[137]^[33] Rectal suppositories, available in strengths such as 100 mg to 500 mg, provide an alternative for patients unable to take oral medications. Intravenous formulations, administered as infusions over 15 minutes or infusions, are used in clinical settings for rapid effect, with doses up to 1000 mg every 6 hours.^[11]^[145] Paracetamol enjoys broad global availability as an over-the-counter (OTC) medication in most countries, reflecting its status on the World Health Organization's Model List of Essential Medicines, where it is recommended in oral liquid (120-125 mg/5 mL), suppository (100 mg), and tablet (100-500 mg) forms for mild to moderate pain and fever management.^[146]^[147] In the United States, it is marketed as acetaminophen under brands like Tylenol, available OTC without quantity limits but with FDA-mandated labeling warnings on overdose risks.^[136] Internationally, brands such as Panadol predominate in regions like Europe, Australia, and Asia, often in similar OTC formulations.^[142] Regulatory variations exist to mitigate overdose risks, particularly from self-poisoning. In Europe, 14 of 21 surveyed countries impose pharmacy pack size limits on OTC paracetamol, ranging from 8 to 30 grams, though non-pharmacy sales may lack such controls.^[148] Similar restrictions apply in Nordic countries, where maximum OTC pack sizes are often capped at 10-24 grams, with larger quantities requiring prescription. In contrast, countries like the United States and Canada permit unrestricted OTC sales, emphasizing consumer education via labeling. High-dose or combination products may necessitate prescriptions in jurisdictions such as the United Arab Emirates for certain formulations. Overall, paracetamol's accessibility supports its role as a first-line analgesic, though pack limits in select regions aim to balance availability with public safety.^[149]^[150]

Public Health and Policy Debates

Paracetamol overdose represents a significant public health challenge, accounting for approximately 46% of acute liver failure cases in the United States and serving as the leading cause in several countries, primarily due to its widespread availability in over-the-counter formulations.^[151] Annually in the US, it prompts around 56,000 emergency department visits, 2,600 hospitalizations, and 500 deaths, often from unintentional supratherapeutic ingestion across multiple products containing the drug.^[72] Policy debates center on mitigating these risks through measures such as enhanced labeling, dose limitations in combination products, and pack size restrictions, weighed against preserving access for therapeutic use in pain and fever management.^[152] In the United Kingdom, legislation enacted in September 1998 capped over-the-counter paracetamol pack sizes at 16 tablets for standard packs and 32 for pharmacist-supervised sales, aimed at curbing self-poisoning suicides.^[153] This intervention correlated with a 43% reduction in paracetamol-related deaths and a 61% drop in liver transplant registrations for overdose within four years post-implementation, with long-term data confirming sustained declines in mortality without substantial substitution to alternative poisons.^[154] Evaluations attribute these outcomes to limiting immediate access to lethal quantities, though overall overdose incidence persisted due to multi-tablet purchases or prescription sources, prompting ongoing discussions on further tightening controls or improving antidote availability like N-acetylcysteine.^[135] Australia implemented pack size reductions effective February 1, 2025, limiting non-pharmacy sales to 16 tablets maximum per pack—down from 20—and pharmacy sales to 50 for acute needs, following Therapeutic Goods Administration decisions in 2023 amid rising overdose hospitalizations (around 225 annually) and 50 deaths.^[155] These changes build on evidence from international precedents, emphasizing suicide prevention while addressing accidental overdoses, particularly in households with children or those with liver vulnerabilities.^[156] In the United States, the Food and Drug Administration has prioritized warnings and formulation limits over broad pack restrictions, mandating since 2014 that prescription acetaminophen-opioid combinations contain no more than 325 mg per dosage unit, which reduced associated acute liver failure hospitalizations by an estimated 20-30%.^[157] Consumer advisories stress not exceeding 4 grams daily and checking labels for hidden sources, yet debates persist on whether educational campaigns suffice against structural risks, with critics advocating European-style pack limits to further curb the 55,000-80,000 annual emergency visits.^[158] Empirical data supports regulatory interventions' efficacy in lowering hepatotoxicity without compromising legitimate use, though implementation varies by jurisdiction balancing individual liberty and population-level harm reduction.^[159]

Research Directions

Emerging Therapeutic Roles

Research into paracetamol's applications beyond analgesia and antipyretia has explored its potential neuroprotective effects, particularly in acute neurological conditions. In critically ill patients with acute ischemic stroke, early administration of paracetamol has been associated with reduced 90-day mortality, potentially through mechanisms involving temperature modulation and mitigation of secondary brain injury, as observed in a retrospective analysis of over 1,000 ICU cases where adjusted hazard ratios indicated a survival benefit (HR 0.72, 95% CI 0.54-0.96).^[160] Similarly, preclinical models of lipopolysaccharide-induced cognitive impairment and d-galactose-induced aging have demonstrated paracetamol's attenuation of neuroinflammation and oxidative stress via downregulation of pro-inflammatory cytokines like TNF-α and IL-1β, alongside preservation of synaptic proteins such as BDNF, suggesting a role in countering cognitive decline.^[161] ^[162] These findings, however, stem largely from animal studies and observational data, with limited randomized clinical trials confirming causality or optimal dosing. High-dose paracetamol regimens, often combined with N-acetylcysteine to prevent hepatotoxicity, have shown preliminary antitumor activity in phase I trials for advanced solid malignancies. In a study of patients with refractory cancers, intravenous doses up to 1,000 mg/kg over 6 hours induced tumor regression in select cases, attributed to selective re-polarization of tumor-associated myeloid cells from pro-tumor M2-like to anti-tumor M1-like phenotypes, without significant off-target effects when rescued with NAC.^[163] ^[164] Conversely, concurrent low-dose use has been linked to diminished efficacy of immune checkpoint inhibitors in non-small cell lung cancer cohorts, possibly via suppression of T-cell activation and cytokine production, as evidenced by propensity score-matched analyses showing poorer progression-free survival (HR 1.45, 95% CI 1.12-1.88).^[165] These conflicting immunomodulatory effects highlight the need for prospective trials to delineate context-specific dosing. Emerging evidence also points to low-dose paracetamol's antidepressant-like properties in rodent models of chronic stress, mediated by enhancement of hippocampal neurogenesis and modulation of the endocannabinoid system, though human trials remain absent.^[166] Cardiovascular investigations, however, reveal no clear benefits and potential risks, including dose-dependent elevations in systolic blood pressure (≈5 mm Hg at 4 g/day) among hypertensive individuals, underscoring paracetamol's limitations outside established indications.^[167] Overall, while mechanistic insights support exploratory roles in neuroprotection and oncology, clinical translation requires rigorous validation to outweigh hepatotoxic liabilities.

Safety and Efficacy Reassessments

A 2015 systematic review and meta-analysis of randomized placebo-controlled trials concluded that paracetamol provides no clinically significant benefit for low back pain and only minimal short-term relief for osteoarthritis of the hip or knee, with mean differences in pain scores of less than 0.5 points on a 10-point scale.^[64] This finding prompted reassessments of its first-line status, as prior guidelines had recommended it broadly for these conditions despite limited evidence of superiority over placebo.^[64] Subsequent overviews in 2021 confirmed modest effects for knee or hip osteoarthritis (mean difference -0.3 points; 95% CI -0.6 to -0.1) but high-quality evidence of ineffectiveness for acute low back pain.^[54] These analyses highlight paracetamol's weak analgesic profile for chronic musculoskeletal pain, questioning its routine use without adjunct therapies.^[37] Safety concerns have intensified beyond acute overdose hepatotoxicity, which remains the primary risk, accounting for 56% of severe acute liver injury cases and involving doses exceeding 150 mg/kg or 12 g in adults, with up to 30% mortality without transplantation.^[168]^[9] Recent observational data link regular long-term use (e.g., 4 g daily) to elevated systolic blood pressure (≈5 mm Hg increase) in hypertensive individuals, correlating with heightened risks of cardiovascular events like heart attack, stroke, or heart failure (from 4.6% baseline).^[167]^[169] Dose-response patterns in follow-up studies reinforce this association, independent of sodium-containing formulations.^[170] Epidemiological studies also report associations between paracetamol exposure—particularly in utero or infancy—and increased asthma risk or exacerbations, with population-attributable risks of 22-38% for symptoms in children, though causation remains debated due to confounding factors like reverse causality in non-experimental designs.^[171]^[172] A 2021 review found modest links to future asthma development from prenatal exposure but inconsistent infancy effects.^[173] Systematic literature syntheses on long-term harms underscore these patterns, urging caution in vulnerable populations despite paracetamol's overall favorable acute safety profile when dosed correctly.^[174] Reassessments advocate weighing these risks against marginal benefits, favoring alternatives like NSAIDs where contraindicated risks (e.g., gastrointestinal) are managed.^[54]

Veterinary Use

Applications in Animals

Paracetamol is employed in veterinary medicine primarily as an analgesic and antipyretic agent in certain species, notably dogs and horses, where it provides mild to moderate pain relief for conditions such as osteoarthritis, post-operative discomfort, and fever.^[175] In dogs, typical oral dosages range from 10–15 mg/kg every 8 hours for short-term use (up to 5 days), with lower doses (10 mg/kg every 12 hours) considered for longer-term therapy to minimize risks like hepatotoxicity. Its use has gained acceptance among UK veterinarians, with surveys indicating a shift toward viewing it as a viable adjunct to other analgesics, though often combined with opioids or NSAIDs for enhanced efficacy.^[176] In horses, paracetamol has demonstrated utility for managing laminitis-associated pain, with a dosage of 10 mg/kg reducing lameness scores without inducing detectable liver damage in controlled studies. Intravenous formulations are explored in dogs for perioperative analgesia as an NSAID alternative, particularly in patients with contraindications to anti-inflammatories, though clinical evidence remains limited and primarily supportive rather than definitive.^[177] Applications extend to livestock monitoring contexts, where residues have been detected in tissues of veal calves and cattle urine, reflecting occasional therapeutic or inadvertent exposure rather than routine dosing.^[178] Use is contraindicated in cats and ferrets due to their deficient glucuronyl transferase activity, which impairs safe metabolism and predisposes to severe methemoglobinemia and oxidative damage even at low doses; accordingly, paracetamol is never recommended for these species in clinical practice.^[179]^[180] In dogs, while generally tolerated at therapeutic levels, monitoring for dose-dependent effects such as vomiting, depression, or elevated liver enzymes is advised, underscoring its role as a secondary rather than first-line option.^[181]

Species-Specific Toxicity

Paracetamol exhibits marked species-specific toxicity primarily due to variations in hepatic metabolism, particularly the conjugation pathways for glucuronidation and sulfation, which detoxify the parent compound and prevent accumulation of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). In species with deficient glucuronyl transferase activity, such as cats, sulfation pathways saturate at low doses, depleting glutathione stores and leading to oxidative damage, methemoglobinemia, and Heinz body anemia. Dogs, with more robust glucuronidation, experience primarily hepatotoxicity at higher doses, while other species like birds, ferrets, and snakes demonstrate extreme sensitivity through distinct mechanisms.^[182]^[183]^[184] Cats (Felis catus) are particularly vulnerable, with toxicity occurring at doses as low as 10 mg/kg orally, and severe effects including cyanosis, facial edema, and hepatic necrosis manifesting within 24-48 hours. Their low levels of high-affinity UDP-glucuronosyltransferase (UGT) enzymes result in minimal glucuronidation (less than 5% of metabolism), forcing reliance on limited sulfation, which rapidly overwhelms at therapeutic human-equivalent exposures. Methemoglobinemia predominates early, with levels exceeding 50% in acute cases, often requiring methylene blue therapy; untreated mortality approaches 100% at doses over 50 mg/kg.^[185]^[183]^[186] In dogs (Canis lupus familiaris), toxicity thresholds are higher, with safe therapeutic doses up to 15 mg/kg every 12 hours for short-term analgesia, but hepatotoxicity emerges at 100-150 mg/kg, and lethality at approximately 150 mg/kg due to centrilobular necrosis and elevated liver enzymes (ALT/AST >1000 IU/L within 24-72 hours). Unlike cats, dogs metabolize paracetamol via glucuronidation (about 40-50%) and sulfation, reducing NAPQI buildup, though methemoglobinemia can occur secondarily in susceptible individuals. Facial and paw edema, vomiting, and hypothermia are common early signs, with N-acetylcysteine as the antidote to replenish glutathione. Breed differences, such as slower clearance in Galgo Español versus Beagles, may influence risk.^[187]^[188]^[189] Other species show variable but often heightened risks: birds, rabbits, ferrets, and pigs develop toxicity from single low doses (e.g., <50 mg/kg), manifesting as rapid hepatic failure and anemia due to inefficient conjugation similar to cats. Snakes exhibit extreme sensitivity independent of feline pathways, with phylogenetic origins linked to deficient detoxification enzymes, causing lethality at microgram-per-kilogram levels used in euthanasia baits. In contrast, rodents like rats tolerate higher doses via efficient alternative metabolism, though mice and hamsters are more prone to in vitro hepatotoxicity. Paracetamol is contraindicated in most non-human primates and equines for similar metabolic limitations, emphasizing the need for species-tailored alternatives in veterinary practice.^[190]^[191]^[192]

References

[1]
Paracetamol (Acetaminophen): mechanisms of action - PubMed
Paracetamol has a central analgesic effect that is mediated through activation of descending serotonergic pathways.
[2]
Paracetamol (acetaminophen): A familiar drug with an unexplained ...
Mar 16, 2021 · The current review gives an update and in some cases challenges the different theories on the pharmacology of paracetamol and raises ...
[3]
Acetaminophen - American Chemical Society
Sep 15, 2014 · It was first prepared by H. N. Morse in 1878. Although many studies on its use as an analgesic were performed, it wasn't until 1950 that it was ...
[4]
Paracetamol: past, present, and future - PubMed
First used clinically by von Mering in 1893, paracetamol did not appear commercially until 1950 in the United States and 1956 in Australia. During the 1960s and ...
[5]
Acetaminophen for Chronic Pain: A Systematic Review on Efficacy
Acetaminophen (paracetamol) is the most commonly used analgesic worldwide and recommended as first-line treatment in all pain conditions by WHO.
[6]
The modern pharmacology of paracetamol: therapeutic actions ...
May 30, 2013 · Paracetamol is, on average, a weaker analgesic than NSAIDs or COX-2 selective inhibitors but is often preferred because of its better tolerance.
[7]
Acute liver failure following paracetamol overdose - PMC
Paracetamol overdose is the leading cause of acute liver failure in the United Kingdom and often presents with extrahepatic organ dysfunction requiring critical ...
[8]
Long‐term adverse effects of paracetamol – a review - McCrae - 2018
Jun 4, 2018 · There does not seem to be evidence for therapeutic paracetamol treatment causing hepatotoxicity, either in healthy individuals or chronic liver ...
[9]
Acetaminophen Toxicity: Practice Essentials, Background ...
Feb 2, 2024 · In adults, an acute ingestion of more than 150 mg/kg or 12 g of acetaminophen is considered a toxic dose and poses a high risk of liver damage.Practice Essentials · Background · Pathophysiology · Etiology
[10]
Acetaminophen | C8H9NO2 | CID 1983 - PubChem - NIH
Molecular Formula. C8H9NO2; HOC6H4NHCOCH3. Synonyms. acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; Tylenol. View More... Molecular Weight. 151.16 g/ ...
[11]
Paracetamol (Acetaminophen) - Pharmaceutical Drugs - NCBI - NIH
Chemical and physical properties of the pure substance. From Fairbrother ... Melting-point: 169–170.5 °C. Solubility: Soluble in water (1:70, 1:20 at 100 ...Chemical and Physical Data · Summary of Data Reported...
[12]
ICSC 1330 - PARACETAMOL - INCHEM
Boiling point: >500°C Melting point: 169-170°C Density: 1.3 g/cm³. Solubility in water, g/100ml at 20°C: 1.4 (moderate) Relative vapour density (air = 1): ...Missing: properties | Show results with:properties
[13]
Acetaminophen | 103-90-2 - ChemicalBook
Melting point 169-171℃, relative density 1.293(21/4℃). Soluble in ethanol, acetone and hot water, difficult to dissolve in water, insoluble in petroleum ether ...
[14]
History of Medicine - Current Medical Issues
On the other hand, paracetamol was first synthesized in 1877 by Harmon Northrop Morse, but it was not until 1887 that clinical pharmacologist Joseph Von Mering ...
[15]
Paracetamol (acetaminophen): A familiar drug with an unexplained ...
It was first synthesized by Joseph von Mering in (1893) by reacting p-nitrophenol with tin and glacial acetic acid. In the 1880s paracetamol and phenacetin (
[16]
Two-Step Synthesis of Paracetamol (Acetaminophen), a Practical ...
Sep 15, 2023 · A practical class, the two-step synthesis of paracetamol, has been devised to illustrate the electrophilic reactivities of carbonyls.Experimental Overview · Hazards · Results and Discussion · Supporting InformationMissing: historical | Show results with:historical
[17]
Life cycle assessment of a process for paracetamol flow synthesis ...
Industrially, paracetamol is widely synthesised via N-acetylation of 4-aminophenol, (Schulman et al., 1975) which can be obtained from the benzene derivatives ...
[18]
The Science of Paracetamol Production - Farmson Basic Drugs
Nov 17, 2023 · One common method for synthesis involves the reaction of p-aminophenol with acetic anhydride. This reaction results in the formation of ...
[19]
US4954652A - Production of acetaminophen - Google Patents
The APAP is formed by a two-step process in which the first step involves reacting 4-hydroxyacetophenone (4-HAP) with a hydroxylamine salt in a base to obtain ...
[20]
Renewables-Based Routes to Paracetamol: A Green Chemistry ...
Oct 21, 2024 · A commonly utilized paracetamol synthesis method in the industry is the Bamberger rearrangement of phenylhydroxylamine (Table 2). Green ...
[21]
Mechanism of action of paracetamol - PubMed
Paracetamol (acetaminophen) is generally considered to be a weak inhibitor of the synthesis of prostaglandins (PGs).
[22]
Acetaminophen - StatPearls - NCBI Bookshelf - NIH
Jan 11, 2024 · Mechanism of Action · Pharmacokinetics · Absorption: Oral acetaminophen is rapidly and efficiently absorbed from the gastrointestinal tract, ...
[23]
Analgesic Effect of Acetaminophen: A Review of Known and Novel ...
Nov 29, 2020 · The main analgesic mechanism of acetaminophen is its metabolization to N-acylphenolamine (AM404), which then acts on the transient receptor potential vanilloid ...Abstract · Introduction · Analgesic Mechanisms of... · Pharmacokinetics and Side...<|separator|>
[24]
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 ...
Acetaminophen inhibited COX-2 by more than 80%, ie, to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.
[25]
Mechanism of action of acetaminophen: is there a cyclooxygenase 3?
Acetaminophen is a weak inhibitor in vitro of both cyclooxygenase (COX)-1 and COX-2, the possibility exists that it inhibits a so far unidentified form of COX, ...
[26]
Paracetamol (Acetaminophen): mechanisms of action
Sep 2, 2008 · Paracetamol has a central analgesic effect that is mediated through activation of descending serotonergic pathways.Missing: pharmacodynamics | Show results with:pharmacodynamics
[27]
Analgesic Effect of Acetaminophen: A Review of Known and Novel ...
Nov 30, 2020 · Moreover, the most possible analgesic mechanism is that the acetaminophen metabolite AM404 acts by activating TRPV1 and/or CB1 receptors. Our ...
[28]
An updated review on the central MoA of Paracetamol | JPR
Mar 29, 2023 · The involvement of the serotonergic pathway in paracetamol action was reported to stem from increasing 5-TH levels in the central structures ...
[29]
New insights into the mechanism of action of acetaminophen
New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 ...
[30]
Paracetamol (acetaminophen): A familiar drug with an unexplained ...
It was first synthesized by Joseph von Mering in (1893) by reacting p-nitrophenol with tin and glacial acetic acid. In the 1880s paracetamol and phenacetin ( ...
[31]
Acetaminophen: Uses, Interactions, Mechanism of Action - DrugBank
One theory is that acetaminophen increases the pain threshold by inhibiting two isoforms of cyclooxygenase, COX-1 and COX-2, which are involved in prostaglandin ...
[32]
Clinical pharmacokinetics of paracetamol - PubMed
In healthy subjects 85 to 95% of a therapeutic dose is excreted in the urine within 24 hours with about 4, 55, 30, 4 and 4% appearing as unchanged paracetamol ...
[33]
Tylenol (acetaminophen) dosing, indications, interactions, adverse ...
Analgesia & Fever. immediate-release. Regular strength: 325-650 mg PO/PR q4hr PRN; not to exceed 3250 mg/day; under supervision of healthcare professional, ...
[34]
IV Acetaminophen for Acute Pain in Emergency Departments - NCBI
It is indicated for the short-term management and treatment of mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and fever.
[35]
[PDF] Recommendations for Management of Acute Dental Pain
➢ MODERATE PAIN: NSAIDs (e.g. ibuprofen 400-800 mg q6h) + acetaminophen (500-650 mg q6h or 1,000 mg q8h) should be utilized as the first line analgesic unless ...
[36]
Unlocking the Optimal Analgesic Potential - NIH
Jul 14, 2023 · Research shows that paracetamol as an analgesic is safe and effective. For example, a previous Cochrane systematic review of oral paracetamol ...<|separator|>
[37]
The efficacy and safety of paracetamol for pain relief - PubMed
Mar 30, 2021 · There is high quality evidence that paracetamol provides modest pain relief for people with knee or hip osteoarthritis (MD, -0.3 points; 95% CI, -0.6 to -0.1 ...
[38]
Efficacy and safety of paracetamol for spinal pain and osteoarthritis
This evidence supports the use of drugs for pain relief to improve ... Clinical guidelines recommend paracetamol as first line analgesic drug for ...
[39]
Paracetamol and Caffeine Combination in Pain Management
Jul 22, 2025 · In clinical trials in patients with mild to moderate acute pain, the combination demonstrates a higher pain relief compared with paracetamol ...Missing: evidence | Show results with:evidence
[40]
Randomized, controlled, multicentre clinical trial of the antipyretic ...
The 1 g paracetamol formulation has a rapid and sustainable antipyretic effect on fever due to infection. Its efficacy is dependent on hepatic metabolism.
[41]
Acetaminophen for Fever in Critically Ill Patients with Suspected ...
Oct 5, 2015 · Our findings suggest that acetaminophen has a modest clinical effect as an antipyretic in ICU patients with fever and probable infection but ...<|separator|>
[42]
Effect of paracetamol (acetaminophen) on body temperature in ...
One study reported that patients with acute ischaemic stroke obtained paracetamol at a daily dose of 6 g within 4 h, and the body temperature was reduced 0.3 °C ...
[43]
Comparison of Acetaminophen (Paracetamol) With Ibuprofen for ...
Oct 30, 2020 · Ibuprofen, compared with acetaminophen, was associated with reduced temperature at less than 4 hours and 4 to 24 hours and less pain at 4 to 24 hours.
[44]
The Antipyretic Effect of High-Dose Paracetamol Versus Mefenamic ...
Jul 11, 2022 · Standard-dose paracetamol (15 mg/kg) had slower and shorter antipyretic effects than high-dose paracetamol and mefenamic acid. The antipyretic ...
[45]
Comparing the Efficacy of Paracetamol, Ibuprofen, and a ... - NIH
Oct 12, 2023 · The combination of paracetamol and ibuprofen showed enhanced effectiveness in fever and pain relief, with minimal adverse effects and no ...
[46]
Paracetamol versus placebo or physical methods for treating fever in ...
This systematic review shows that inconsistent and weak evidence supports the use of paracetamol to reduce fever in children. This does not mean that ...
[47]
Fever therapy in febrile adults: systematic review with meta-analyses ...
Jul 12, 2022 · To investigate the effects of fever therapy compared with no fever therapy in a wide population of febrile adults.
[48]
Faster recovery and reduced paracetamol use – a meta-analysis of ...
Apr 23, 2019 · Consequently, current guidelines recommend against using antipyretic agents with the sole aim of reducing body temperature in children with ...
[49]
Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and ...
The results of the studies analyzed in this review mostly support paracetamol efficacy in ductal closure, with inconstant low and transient elevation of liver ...
[50]
Paracetamol (acetaminophen) for patent ductus arteriosus in ...
Dec 15, 2022 · Randomized controlled trials (RCTs) have suggested that paracetamol may be an effective and safe agent for the closure of a PDA.Missing: indications | Show results with:indications
[51]
Acetaminophen Therapy for Persistent Patent Ductus Arteriosus
May 1, 2021 · (70) Current evidence suggests that acetaminophen is as effective as indomethacin and ibuprofen in PDA closure in preterm infants older than 28 ...
[52]
Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality ...
Jul 16, 2024 · Off-label use of paracetamol in managing patent ductus arteriosus across neonatal intensive care units in the UK . Arch Dis Child Fetal Neonatal ...
[53]
Paracetamol versus placebo for knee and hip osteoarthritis - PubMed
Feb 25, 2019 · Based on high-quality evidence this review confirms that paracetamol provides only minimal improvements in pain and function for people with hip or knee ...
[54]
The efficacy and safety of paracetamol for pain relief: an overview of ...
Apr 5, 2021 · There is high quality evidence that paracetamol provides modest pain relief for people with knee or hip osteoarthritis (MD, –0.3 points; 95% CI ...
[55]
Paracetamol as first line for treatment of knee and hip osteoarthritis
The review included 10 trials with 3541 participants and reported that paracetamol did not result in clinically important improvements in pain: MCID 3% (95% CI: ...
[56]
Oral paracetamol (acetaminophen) for cancer pain - PubMed Central
There is no evidence to show that paracetamol is useful in treating people with cancer pain, either alone or combined with a morphine‐like drug. Nor is there ...
[57]
Acetaminophen: Beyond Pain and Fever-Relieving - Frontiers
Nov 8, 2011 · Acetaminophen exhibits both analgesic and antipyretic properties and has been widely used as an active ingredient in many approved drugs.
[58]
Intravenous paracetamol (acetaminophen) for pain after surgery in ...
May 23, 2016 · This review provides high quality evidence that a single dose of either IV paracetamol or IV propacetamol provides around four hours of effective analgesia.
[59]
Effects of acetaminophen and ibuprofen monotherapy in febrile ...
Aug 22, 2021 · Pooled estimates demonstrated that acetaminophen led to significantly lower fever resolution rates than ibuprofen did (POR=0.91, 95%CI: 0.84– ...
[60]
A Randomized Placebo-Controlled Trial of Acetaminophen for ...
The results of this relatively small trial suggest that acetaminophen may reduce the risk of post-vaccination fever and fussiness.Missing: evidence RCT
[61]
Single dose paracetamol (acetaminophen), with and without ...
Paracetamol is an effective analgesic with a low incidence of adverse effects. The addition of codeine 60 mg to paracetamol produces additional pain relief even ...
[62]
Clinical and Economic Evidence for Intravenous Acetaminophen
May 8, 2012 · 30 The pivotal trial in the United States showed that intravenous acetaminophen was more effective for pain relief and reduced morphine ...
[63]
Efficacy and safety of paracetamol for spinal pain and osteoarthritis
Mar 31, 2015 · Conclusions Paracetamol is ineffective in the treatment of low back pain and provides minimal short term benefit for people with osteoarthritis.
[64]
Paracetamol Side Effects: Common, Severe, Long Term - Drugs.com
The most commonly reported adverse reactions have included nausea, vomiting, constipation.
[65]
Acetaminophen (oral route, rectal route) - Side effects & dosage
Acetaminophen is used to treat minor aches and pain and to reduce fever. It may also help treat pain from mild forms of arthritis.Missing: evidence | Show results with:evidence
[66]
Paracetamol - Alcohol and Drug Foundation
Jun 6, 2025 · The most common side effects of paracetamol are: Drowsiness and fatigue; Rashes and itching2. Children may occasionally experience low blood ...What is paracetamol? · Effects of paracetamol · Overdose
[67]
Paracetamol: not as safe as we thought? A systematic literature ...
Several large observational studies confirm a better side effect profile for paracetamol compared with traditional NSAIDs.
[68]
Mechanisms of acetaminophen hepatotoxicity and their translation ...
APAP hepatotoxicity is initiated by its conversion to the reactive intermediate NAPQI, which results in glutathione depletion and formation of APAP protein ...
[69]
Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update
Jun 15, 2016 · The hepatotoxicity of APAP rests predominantly with the highly toxic and reactive compound NAPQI, which forms covalent bonds with sulfhydryl ...
[70]
Hepatotoxicity induced by acute and chronic paracetamol overdose ...
Chronic paracetamol poisoning may be a potential risk factor for the hepatotoxicity, including acute liver failure.<|separator|>
[71]
Acetaminophen Toxicity - StatPearls - NCBI Bookshelf
Apr 10, 2025 · Acetaminophen toxicity is the second most common cause of liver transplantation worldwide and the most common cause of liver failure in the United States.
[72]
Impact of Liver Disease, Alcohol Abuse, and Unintentional ...
Acetaminophen-related hepatotoxicity is more common in patients with unintentional overdoses, alcohol abuse, and underlying liver disease.
[73]
Full article: Paracetamol (acetaminophen) overdose and hepatotoxicity
A large retrospective study in the US found significantly increased risk of acute liver injury in people infected with hepatitis C virus, and people with ...
[74]
Liver injury induced by paracetamol and challenges associated with ...
While the risk of liver failure may be increased in the case of chronic alcoholism in combination with paracetamol overdose, alcoholism does not necessarily ...
[75]
PARACETAMOL = ACETAMINOPHEN oral - MSF Medical Guidelines
Dosage · Child under 1 month: 10 mg/kg 3 or 4 times daily (max. 40 mg/kg daily) · Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily) · Adult ...<|separator|>
[76]
Knowledge and Practices of Paracetamol Administration Among ...
Administration of supratheraputic doses of paracetamol was common (43%). Children above 3 years are at an increased risk of receiving a supra therapeutic dose.
[77]
Paracetamol (acetaminophen) use in infants and children was never ...
Paracetamol is widely believed to be safe for infants and children when used as directed, despite mounting evidence in humans and in laboratory animals ...
[78]
What dose of paracetamol for older people?
The usual adult dose for oral paracetamol is 0.5 to 1g every 4–6 hours up to a maximum of 4g in 24 hours with no dose reduction advised for older people.
[79]
Evaluation of the evidence on acetaminophen use and ...
Aug 14, 2025 · Acetaminophen (also known as paracetamol) is currently considered the only pain and fever reducer indicated for use during pregnancy because of ...
[80]
Acetaminophen Use During Pregnancy and Children's Risk of ...
Apr 9, 2024 · Acetaminophen use during pregnancy was not associated with children's risk of autism, ADHD, or intellectual disability in sibling control analysis.Missing: lactation | Show results with:lactation
[81]
FDA Responds to Evidence of Possible Association Between Autism ...
Sep 22, 2025 · Evidence in recent years has suggested a correlation between acetaminophen use during pregnancy and subsequent diagnosis of conditions like ...
[82]
SMFM Statement on Acetaminophen Use During Pregnancy and ...
Sep 3, 2025 · Pregnant patients can be reassured that using acetaminophen to treat pain and fever is safe. # # #. About SMFM<|separator|>
[83]
Acetaminophen - Drugs and Lactation Database (LactMed®) - NCBI
Sep 15, 2025 · Giving acetaminophen and ibuprofen on a fixed schedule for 24 hours after vaginal delivery appears to increase the breastfeeding rate.
[84]
What is the recommended dose adjustment for paracetamol ...
Jun 4, 2025 · No dose adjustment for paracetamol (acetaminophen) is typically required in patients with renal impairment for standard short-term use.
[85]
Full article: Paracetamol-induced acute kidney injury in the absence ...
Sep 5, 2022 · This study demonstrates that clinically relevant AKI due to paracetamol overdose rarely occurs without concomitant hepatic injury.
[86]
[DOC] The American Association for the Study of Liver ... - Regulations.gov
Both comment and data on specific dosage for safe and effective use of acetaminophen in people who consume alcohol. AASLD believes that the proposed ...
[87]
Paracetamol toxicity • LITFL • Toxicology Library Toxicant
Toxic Mechanism: The main toxicity following paracetamol poisoning is acute liver injury which results from the formation of a toxic metabolite of ...Acute Paracetamol Toxicity · N-acetylcysteine · Liver Transplantation for...
[88]
Paracetamol toxicity - Deranged Physiology
Feb 14, 2024 · Mechanism of paracetamol toxicity · Most paracetamol is metabolised by glucouronidation and sulfation · Some (~5%) is metabolised by CYP2E1 · In ...<|separator|>
[89]
Acetaminophen Toxicity Clinical Presentation - Medscape Reference
Feb 2, 2024 · In phase 1 (0.5-24 hours after ingestion), patients may be asymptomatic or report anorexia, nausea or vomiting, and malaise. Physical ...
[90]
Acetaminophen Toxicity Treatment & Management
Feb 2, 2024 · Guidelines from the American College of Emergency Physicians recommend the use of NAC to treat acute acetaminophen overdose in patients with ...
[91]
Management of Acetaminophen Poisoning in the US and Canada
Aug 8, 2023 · Differences from current US practice include defining acute ingestion as an ingestion presentation from 4 to 24 hours after overdose was ...
[92]
Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen ...
Dec 15, 1988 · We conclude that N-acetylcysteine treatment should be started within eight hours of an acetaminophen overdose, but that treatment is still indicated at least ...
[93]
Acetaminophen (paracetamol) poisoning: Management in adults ...
Jun 30, 2025 · - Modified King's College Criteria · Acute kidney injury · PATIENT WITH IATROGENIC INTRAVENOUS OVERDOSE · PATIENT WITH HIGH-RISK INGESTION.
[94]
Acetylcysteine for Acetaminophen Poisoning - PMC - NIH
Acetaminophen poisoning can be due to ingestion of a single overdose (usually as an attempt at self-harm) or ingestion of excessive repeated doses or too- ...
[95]
Independent review of paracetamol overdose
Sep 14, 2022 · Recent data shows that each year in Australia, paracetamol overdose leads to around nine people per million hospitalised with liver injury and ...
[96]
Acetaminophen Poisoning - DynaMed
May 11, 2025 · Acetaminophen (paracetamol) may be the most common cause of acute, unintentional medication poisoning in children ≤ 7 years old in Israel from 2009 to 2017.
[97]
Effect of the UK's revised paracetamol poisoning management ... - NIH
It is estimated that between 82 000 and 90 000 patients present in the UK each year with paracetamol overdose 3–5. Between 150 and 250 deaths occur annually, ...
[98]
Paracetamol poisoning - Wikipedia
NAPQI decreases the liver's glutathione and directly damages cells in the liver. Diagnosis is based on the blood level of paracetamol at specific times after ...Cause · Diagnosis · Prevention · Treatment<|separator|>
[99]
Smaller packs of paracetamol have reduced overdose deaths by 43%
Feb 8, 2013 · UK legislation to limit paracetamol pack sizes has seen a 43% reduction in the number of deaths due to paracetamol overdoses, a study led by Oxford University ...
[100]
Still dealing with paracetamol overdoses: epidemiology and quality ...
Jul 4, 2025 · This study aimed to use Scottish data on Accident & Emergency (A&E) attendances (2020–2023) and hospital admissions (2010–2021) for paracetamol-only overdosing.
[101]
Long-term mortality of acetaminophen poisoning - PubMed Central
Jan 8, 2018 · APAP poisoning was associated with increased long-term mortality. Early referral for intensive aftercare and associated interventions are suggested.Missing: global | Show results with:global
[102]
Paracetamol poisoning‐related hospital admissions and deaths in ...
Sep 2, 2019 · 126 in‐hospital deaths were recorded in the NHMD, and 205 deaths (in‐hospital and out of hospital) in the NCIS, with no temporal trends.<|separator|>
[103]
Paracetamol toxicity: epidemiology, prevention and costs to the ...
Since then the incidence of poisoning has increased, and paracetamol is now the most common drug in self‐poisoning, with a high rate of morbidity and mortality.Abstract · History · How common is paracetamol... · Measures to reduce toxicity
[104]
Drug interactions with paracetamol - PubMed
No serious adverse drug interactions with therapeutic doses of paracetamol have been confirmed in humans.
[105]
Pharmacological modification of gastric emptying - PubMed
The rate of paracetamol absorption depends on the rate of gastric emptying. Propantheline delayed gastric emptying and markedly slowed the absorption of ...
[106]
Drug Interactions between atropine and Paracetamol - Drugs.com
Anticholinergic agents may delay and/or decrease the gastrointestinal absorption of acetaminophen by reducing gastric motility and delaying gastric emptying.
[107]
Pharmacological Modification of Gastric Emptying: Effects ... - The BMJ
Mar 10, 1973 · Conversely, the absorption of paracetamol in five healthy volunteers was accelerated by metoclopramide, a drug which stimulates gastric emptying ...
[108]
Pharmacokinetic interaction between acetaminophen and ... - PubMed
Lansoprazole hastens the absorption of acetaminophen solution, but little modifies its elimination rate and bioavailability.
[109]
The Risk of Drug‐Drug Interactions with Paracetamol in a ...
Jan 20, 2020 · The drugs found to interact with paracetamol in the Swedish study were carbamazepine, phenytoin, and phenobarbital. It is striking that none of ...
[110]
PharmGKB summary: Pathways of acetaminophen metabolism at ...
Acetaminophen disposition involves a complex inter-organ transport of metabolites between the liver, kidney and intestine, through bile and the blood stream, to ...
[111]
The effect of probenecid on paracetamol metabolism and ... - PubMed
Pretreatment with probenecid caused a significant decrease in paracetamol clearance (6.23 to 3.42 ml.min-1.kg-1). The urinary excretion of paracetamol sulphate ...
[112]
https://medicinesinformation.co.nz/bulletins/pharmacokinetic-medicines-interactions-with-probenecid/
[113]
Kinetics and metabolism of paracetamol and phenacetin.
The plasma half-life of paracetamol is not increased in patients with impaired renal function, but there is accumulation and retention of conjugates (Prescott,.<|control11|><|separator|>
[114]
Paracetamol, alcohol and the liver - PubMed
Many alcoholic patients reported to have liver damage after taking paracetamol with 'therapeutic intent' had clearly taken substantial overdoses. No proper ...
[115]
Paracetamol, alcohol and the liver - Prescott - 2000
Dec 24, 2001 · It is claimed that chronic alcoholics are at increased risk of paracetamol (acetaminophen) hepatotoxicity not only following overdosage but also with its ...
[116]
The Risk of Drug-Drug Interactions with Paracetamol in a Population ...
Jan 19, 2020 · The patient at risk of a pDDI with paracetamol and phenytoin experienced clinical incidents of both pain and decreased liver function. This ...
[117]
Acetaminophen interactions to avoid - SingleCare
Nov 30, 2023 · Acetaminophen interactions can increase the risk of liver damage, especially when combined with drugs that affect its metabolism or are toxic to ...Acetaminophen-Drug... · Antiepileptics · Other Acetaminophen...
[118]
Interaction between paracetamol and warfarin in patients - PubMed
Together with the rise in INR on paracetamol treatment there were significant reductions in the vitamin K-dependent clotting factors II, VII, IX and X.
[119]
Interaction between Paracetamol and Warfarin: A Double-Blind ...
Paracetamol at 4g/d induced a significant increase in INR in patients on a stable anticoagulation with warfarin. It results in an increase in the risk of ...
[120]
INR Monitoring After Starting Paracetamol in Patients on Warfarin
Oct 7, 2025 · Paracetamol co-administration increases INR in a dose-dependent manner, with significant increases observed by day 3 of therapy 1 · In randomized ...
[121]
Acetaminophen and warfarin: A recipe for supratherapeutic ...
When acetaminophen is combined with warfarin, supratherapeutic international normalized ratio (INR) may result in an increased risk of postoperative bleeding.
[122]
Paracetamol decreases steady‐state exposure to lamotrigine by ...
Nov 20, 2015 · Paracetamol statistically significantly induced steady-state lamotrigine glucuronidation, resulting in a 20% decrease in total systemic exposure ...
[123]
Paracetamol and warfarin Interactions - Drugs.com
Using acetaminophen together with warfarin is generally considered safe. However, the risk for bleeding may increase if higher dosages of acetaminophen (more ...
[124]
History and Interaction of Parcetamol - Hilaris Publisher
Jul 30, 2021 · Harmon Northrop Morse synthesized paracetamol at Johns Hopkins University thru the discount of p-nitro phenol with tin in glacial acetic acid ...
[125]
Paracetamol book | Background information - RSC Education
Many medicines were synthesised to try to improve on phenacetin and as early as 1893 Joseph von Mering made paracetamol. N-ethanamide paracetamol. He found ...
[126]
Paracetamol: The History Of A Common Pain Reliever
Dec 6, 2023 · Paracetamol can be synthesised using the classic laboratory method of reducing p-nitrophenol with the aid of tin in glacial acetic acid. ...
[127]
HISTORY OF PARACETAMOL ...
Dec 21, 2016 · In 1893, paracetamol was discovered in the urine of individuals who had taken phenacetin, and was concentrated into a white, crystalline ...
[128]
4 The rediscovery of paracetamol - Oxford Academic
This was an important breakthrough in the history of paracetamol (acetaminophen), which was synthesized in 1878 but only clinically used in 1955.
[129]
Drug Therapeutics & Regulation in the U.S. - FDA
Jan 31, 2023 · The commercialization of acetaminophen by von Mering in 1893 provided a safer combined pain reliever and fever reducer and decreased the ...
[130]
A First? Orange Book Patent Delisting Counterclaim Denied in ...
The '218 patent is improperly listed in the Orange Book for OFIRMEV because it “only consists of process claims and a single product-by-process claim directed ...
[131]
Acetaminophen Intoxication: A Critical-Care Emergency
Dec 16, 2016 · When acetaminophen was introduced to the U.S. market in 1947, it was available only by prescription. In 1960, its status was changed to OTC.Acetaminophen History And... · Pathophysiology · Treatment
[132]
Use Only as Directed - ProPublica
Sep 20, 2013 · As early as the 1970s, an FDA panel had examined whether to put an alcohol warning on the acetaminophen label. In 1978, according to an internal ...
[133]
Impact of different pack sizes of paracetamol in the United Kingdom ...
In order to reduce fatal self-poisoning legislation was introduced in the UK in 1998 to restrict pack sizes of paracetamol sold in pharmacies (maximum 32 ...
[134]
Paracetamol (acetaminophen) pack size restrictions and poisoning ...
Sep 14, 2007 · Background and Objective: In September 1998, legislation was introduced in the United Kingdom to limit paracetamol pack sizes to 16 tablets ...<|control11|><|separator|>
[135]
Long term effect of reduced pack sizes of paracetamol on poisoning ...
Feb 7, 2013 · UK legislation to reduce pack sizes of paracetamol was followed by significant reductions in deaths due to paracetamol overdose.
[136]
Acetaminophen - FDA
Aug 14, 2025 · Acetaminophen is a drug that is used to: Temporarily relieve pain; Temporarily reduce fever. Acetaminophen is found in hundreds of over-the- ...
[137]
Over-the-counter (OTC) medicine monograph: Paracetamol for oral ...
Sep 6, 2013 · This OTC Medicine Monograph outlines the requirements for Australian market authorisation of oral medicines containing paracetamol as a single active ...Directions For Use · Quality Requirements · Finished Product...
[138]
FDA issues agency-initiated proposed order regarding OTC ...
Aug 7, 2024 · The 2017 guidance recommended the addition of language in product labeling warning consumers that acetaminophen may cause severe skin reactions,.
[139]
Paracetamol | C8H9NO2 - ChemSpider
Paracetamol ; Molecular formula: C8H9NO2 ; Average mass: 151.165.
[140]
Acetaminophen | The Merck Index Online
Molecular formula: C8H9NO2; Molecular weight: 151.17; Percent composition: C ... Download Image (.png) Download Structure (.mol). *The name THE MERCK INDEX ...Missing: IUPAC | Show results with:IUPAC
[141]
What Is Acetaminophen vs. Paracetamol? Uses & Side Effects
Both drugs are chemically the same: C8H9NO2. The drug is called acetaminophen in the United States and Japan, and paracetamol in Europe and most of the rest of ...
[142]
What is paracetamol / Panadol called in the US? - Drugs.com
Jan 8, 2025 · It is available as brand names such as Tylenol, Mapap or Panadol, and also as generics and store-specific brands. There are no differences ...Missing: global | Show results with:global
[143]
Paracetamol Uses, Dosage, Side Effects, Warnings - Drugs.com
Sep 23, 2025 · Serious side effects of paracetamol include: Allergic reactions, which may be severe and include: Skin rashes, itching, or hives. Swelling of ...Side effects · Paracetamol Interactions · Paracetamol Patient Tips · Fever
[144]
Paracetamol for adults: painkiller for pain and high temperature - NHS
Paracetamol for adults - Brand names: Disprol, Hedex, Medinol, Panadol. Find out how paracetamol for adults treats aches, pains and high temperature, ...Missing: global | Show results with:global
[145]
Paracetamol - an overview | ScienceDirect Topics
Paracetamol is available in oral (elixir/tablet), intravenous and rectal formulations. The oral route is frequently used as it has high bioavailability (F > 0.9 ...
[146]
Paracetamol (acetaminophen) - Electronic Essential Medicines List
Paracetamol is a non-opioid analgesic for treatment of mild to moderate pain including dysmenorrhoea and headache; pain relief in osteoarthritis and soft ...
[147]
WHO Model List of Essential Medicines - 23rd list, 2023
Jul 26, 2023 · The WHO Model List of Essential Medicines and Model List of Essential Medicines for Children are updated and published every two years.
[148]
Availability of Paracetamol Sold Over the Counter in Europe - PubMed
This study examined how widely pack size restrictions of paracetamol sold over the counter have been implemented in Europe and also availability of paracetamol ...
[149]
[PDF] Trends in Use of Paracetamol in the Nordic Countries
Mar 1, 2018 · Overview of legislation and restrictions regarding OTC paracetamol sales in the different countries during the study period. Available. OTC.<|separator|>
[150]
What medication can I take to Dubai and which ... - Aetna International
Codeine is a controlled drug in the UAE, so you will need permission to take co-codamol (paracetamol and codeine) into the country.
[151]
Public Health: Acetaminophen (APAP) Hepatotoxicity—Isn't It Time ...
APAP toxicity accounts for 46% of all acute liver failure (ALF) in the United States and between 40 and 70% of all cases in Great Britain and Europe.Missing: policy | Show results with:policy
[152]
Don't Overuse Acetaminophen - FDA
Feb 1, 2024 · Taking too much acetaminophen can lead to overdose and severe liver damage. Symptoms of acetaminophen overdose may include nausea, vomiting, abdominal pain, ...
[153]
Pack size and paracetamol overdose: 16 years later - PubMed
In 1998 the United Kingdom limited the availability of paracetamol sold over-the-counter in an effort to reduce serious paracetamol overdose.
[154]
UK legislation on analgesic packs: before and after study of long ...
Main outcome measures Deaths by suicidal overdose with paracetamol, salicylates, or ibuprofen; numbers of patients admitted to liver units, listed for liver ...
[155]
TGA makes final decision to reduce paracetamol pack sizes
May 3, 2023 · Each year in Australia around 225 people are hospitalised with liver injury and 50 Australians die from paracetamol overdose, with rates of ...Missing: UK | Show results with:UK
[156]
Paracetamol restrictions updated as self-harm levels remain high in ...
Jan 20, 2025 · From 1 February 2025, packs of paracetamol will contain fewer tablets, both in pharmacies and in other places that paracetamol is sold.
[157]
Limiting Acetaminophen in Prescription Combination Opioid Products
Mar 7, 2023 · The FDA mandate to limit acetaminophen to 325 mg/tablet in prescription combination acetaminophen and opioid medications was associated with a decline in ...Missing: debates regulation
[158]
Prescription Acetaminophen Products to be Limited to 325 mg ... - FDA
Feb 7, 2018 · Data Summary and Discussion From 1998 to 2003, acetaminophen was the leading cause of acute liver failure in the United States, with 48% of ...
[159]
Legal limits for paracetamol sales - The Lancet
There is strong evidence that restricting the availability of paracetamol reduces morbidity and mortality from paracetamol overdose.Missing: debates | Show results with:debates
[160]
Early acetaminophen Use and 90-day mortality in ICU patients with ...
The findings of our study suggest that acetaminophen use may be associated with improved prognosis in critically ill patients with acute ischemic stroke ...<|separator|>
[161]
Acetaminophen attenuates lipopolysaccharide-induced cognitive ...
Jan 21, 2017 · Our results suggest that APAP may possess a neuroprotective effect against LPS-induced cognitive impairment and inflammatory and oxidative stress.
[162]
Neuroprotective effect of low-dose paracetamol treatment against ...
Conclusion. Low-dose APAP treatment has a neuroprotective effect on cognitive dysfunction in the d-gal aging model, and the underlying molecular mechanisms ...Missing: clinical | Show results with:clinical
[163]
High-Dose Acetaminophen as a Treatment for Cancer - MDPI
Jan 31, 2024 · The use of high-dose acetaminophen (AAP) with n-acetylcysteine (NAC) rescue was studied as an anti-cancer treatment in phase I trials with promising signals of ...
[164]
High dose acetaminophen re-polarizes CD11b+ cells in the tumor ...
High dose acetaminophen (AAP) has demonstrated promising results in early phase clinical trials for treatment of advanced malignancies.
[165]
Effects of Acetaminophen Exposure on Outcomes of Patients ...
Sep 1, 2023 · Effects of acetaminophen exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small-cell lung cancer: a propensity score- ...2.1. Study Design And... · 3. Results · Table 3<|separator|>
[166]
Low doses of acetaminophen produce antidepressive-like effects ...
Jul 9, 2024 · Our findings demonstrated that acetaminophen in lower doses but not high doses revealed an antidepressant-like activity without inducing tolerance and ...
[167]
Regular Acetaminophen Use and Blood Pressure in People With ...
Feb 7, 2022 · Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo.Missing: benefits | Show results with:benefits
[168]
Paracetamol (acetaminophen) overdose and hepatotoxicity - PubMed
Where data were available, we estimate that paracetamol is involved in 6% of poisonings, 56% of severe acute liver injury and acute liver failure, and 7% of ...Missing: statistics | Show results with:statistics
[169]
Regular paracetamol use linked to higher blood pressure - BHF
Feb 7, 2022 · Long-term paracetamol use could increase the risk of heart disease and strokes in people with high blood pressure, according to research we've funded.
[170]
Paracetamol and adverse cardiovascular outcomes in patients with ...
Oct 28, 2024 · Paracetamol was associated with adverse cardiovascular outcomes both in short-term and long-term follow-up with a dose-response relationship.Missing: benefits evidence
[171]
Association between paracetamol use in infancy and childhood, and ...
Sep 20, 2008 · Use of paracetamol was similarly associated with the risk of severe asthma symptoms, with population-attributable risks between 22% and 38%.
[172]
The association between paracetamol use and asthma: causation or ...
Sep 14, 2014 · One potential causative factor is the use of paracetamol. Most of the evidence for the link with asthma is from non-experimental studies of ...
[173]
Paracetamol exposure and asthma: What does the evidence say ...
Aug 23, 2021 · There is a modest association between paracetamol exposure in-utero and the future development of asthma. Exposure in infancy has a less consistant association.
[174]
Paracetamol: not as safe as we thought? A systematic literature ...
The objective of this review was to synthesise the long-term observational evidence of the harmful effects of paracetamol. Findings from this systematic review ...
[175]
Paracetamol: A Focus on Dogs - Science Publications
Nov 2, 2021 · Paracetamol is used in dogs as an analgesic, antipyretic, and for post-operative pain, but should be used with caution due to potential ...
[176]
Current perceptions and use of paracetamol in dogs among ...
Paracetamol is widely used by veterinarians working in the UK. Most veterinarians have changed their perception on the use of paracetamol over the last decade ...
[177]
Assessing the use of IV paracetamol as an alternative to NSAIDs for ...
Apr 17, 2025 · The papers studied provide limited and weak evidence to suggest that IV paracetamol provides peri- and post-operative analgesia in dogs.
[178]
Application of a generic PBK model for beef cattle: Tissue/fluid ...
Lately, residues of acetaminophen (paracetamol) have been found in urine, kidney, and meat tissue from veal calves as well as in urine of cattle and pigs (Groot ...
[179]
Acetaminophen (Tylenol®) | Dog, Cat, Pet Medication - PetMD
Apr 21, 2023 · Acetaminophen is rarely used in dogs/horses for pain/fever, but is toxic to cats. It can cause liver damage in dogs and is not FDA-approved for ...
[180]
Get the Facts about Pain Relievers for Pets - FDA
Sep 29, 2022 · Veterinarians will sometimes use acetaminophen to relieve pain in dogs, but never in cats. Acetaminophen is fatal to cats. Cats should never be ...
[181]
Nonsteroidal Anti-inflammatory Drugs in Animals - Pharmacology
They are routinely used for the relief of pain and inflammation associated with osteoarthritis in dogs and horses and for colic, navicular disease, and ...
[182]
The diagnosis of acetaminophen toxicosis in a cat - PMC - NIH
In most mammals, acetaminophen exposure becomes toxic when glucuronidation and sulfation pathways become saturated and cellular glutathione stores are depleted ...
[183]
Molecular basis for deficient acetaminophen glucuronidation in cats ...
Cats have low high-affinity acetaminophen-UGT levels, resulting in poor glucuronidation and susceptibility to acetaminophen toxicity.
[184]
Toxicoses From Human Analgesics in Animals - Toxicology
Acute ingestions of human analgesics are reported to animal poison control centers daily. Dogs are the species most often involved, followed by cats, ferrets, ...
[185]
Acetaminophen Toxicity in Cats | VCA Animal Hospitals
Since cats are not able to efficiently metabolize acetaminophen, they are more vulnerable to toxicity. Cats develop toxicity at much lower doses than dogs. What ...
[186]
The toxicity and biotransformation of single doses of acetaminophen ...
Hepatic centrilobular pathology was seen in dogs, while cats had more diffuse liver pathologic changes. The results indicate that the cat is at increased risk ...
[187]
Acetaminophen Toxicity in Dogs | VCA Animal Hospitals
Acetaminophen (Tylenol), a common human drug used to control pain in fever, can be poisonous to dogs if inappropriate doses are given.
[188]
Paracetamol poisoning in dogs: clinical signs and consequences
A 15 mg/kg therapeutic dose of paracetamol has been established for dogs. By contrast, a dose of 150 mg/kg is lethal for dogs.
[189]
[PDF] Paracetamol: A Focus on Dogs - Science Publications
Sep 28, 2021 · This study is a documentation of the therapeutic, toxic and lethal doses of APAP in dogs, as well as the therapeutic effects, clinical ...
[190]
Acetaminophen Toxicity in Pets | Sanford Veterinarian Blog
A single dose of acetaminophen can be toxic or deadly to any animal species, including dogs, cats, birds, rabbits, ferrets, pigs, and other animals.
[191]
Phylogenetic origins for severe acetaminophen toxicity in snake ...
The extreme sensitivity for acetaminophen in snakes is based on a different phylogenetic origin than the sensitivity observed in cats.
[192]
Species differences in the hepatotoxicity of paracetamol are due to ...
Whereas paracetamol readily caused cell blebbing and a loss of viability in hepatocytes from mouse and hamster, human and rat hepatocytes were much more ...
[193]
Towards an Effective and Safe Treatment of Inflammatory Pain
Review highlighting paracetamol's advantages including no development of tolerance.